DELFI Diagnostics Launches Assay That May Improve Monitoring of Cancer Treatment Response

Posted on by admin

DELFI-Tumor Fraction assay was developed to improve noninvasive assessment of tumor burden and monitoring of treatment efficacy and resistance in patients with advanced cancers.

Leave a Reply

Your email address will not be published. Required fields are marked *